Abstract 460P
Background
Cancer diagnosis and treatment can give rise to psychological challenges for patients. Amidst the adversity, there exists the potential for post-traumatic growth (PTG), a phenomenon characterized by positive psychological changes and personal development following traumatic experiences. Group-based interventions have emerged as a promising avenue for fostering PTG among individuals with cancer. This systematic review aims to assess the group-based interventions designed to facilitate PTG in cancer patients.
Methods
A comprehensive search was conducted among PubMed, EMBASE, Science Direct, and Scopus. Keywords used were group-based intervention, group therapy, PTG, positive psychological change, and cancer. Publications were limited to English manuscripts published in the last 10 years. Quality of each studies were assessed with Newcastle-Ottawa Scale (NOS).
Results
This review encompassed a selection of 12 studies, with 970 individuals aged above 18 years. The sampled patients displayed wide cancer types, including breast, gynaecologic, hematologic, head and neck, gastrointestinal, urological, and lymphoma. Group therapies in this review were mindfulness-based psychotherapy, cognitive behavioural stress management, acceptance and commitment therapy, supportive and positive group therapy, art and relaxation response resiliency mind-body program, varied from 5-12 sessions. The primary assessment tool is Post-Traumatic Growth Inventory (PTGI). The findings suggest that group interventions contribute to the personal strength, positive affect, and sense of meaning in cancer-related trauma. While positive trends were observed, the magnitude of PTG outcomes varied, likely influenced by duration, composition, and participant readiness for growth.
Conclusions
To conclude, this systematic review assesses the potential of group-based interventions as resource in promoting PTG among cancer patients. Nevertheless, the variations in outcomes across studies emphasize the need for interventions, accounting for individual differences. This review contributes to our understanding of the relationship between group-based interventions and PTG among cancer patients, paving the way for further research.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
D. G. William.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
227P - Proteomic analysis of urothelial lesions reveals novel diagnostic biomarkers to distinguish pathologic pitfalls and protein-protein interactions
Presenter: Changlim Hyun
Session: Poster Display
Resources:
Abstract
228P - Real-world data on dose adjustment of cabozantinib in advanced renal cell carcinoma
Presenter: Hemavathi Baskarane
Session: Poster Display
Resources:
Abstract
229P - The application of diffusion kurtosis imaging in predicting muscle invasion of bladder cancer: A comparison with conventional DWI
Presenter: Shuai Jiang
Session: Poster Display
Resources:
Abstract
230P - Oncological outcomes between partial cystectomy and radical cystectomy in solitary muscle invasive bladder cancer with downgraded T stage
Presenter: Ming Wei Hsu
Session: Poster Display
Resources:
Abstract
231P - BMI-predicted progression-free survival after pembrolizumab therapy for urothelial cancer: Asian version of BMI classification is suitable for Asian patients
Presenter: mirii harada
Session: Poster Display
Resources:
Abstract
232P - The immunosuppressive features of the 20S Proteasome β-subunit gene family in von Hippel-Lindau (VHL)-mutated clear cell renal cell carcinoma (ccRCC): A TCGA-based bioinformatics study
Presenter: Saja Alzghoul
Session: Poster Display
Resources:
Abstract
233P - The crosstalk between PBRM1 loss and tumor immune microenvironment (TIME) of clear cell renal cell carcinoma (ccRCC): A possible interconnection to immunotherapy response
Presenter: Ahmed Al Sharie
Session: Poster Display
Resources:
Abstract
235P - Do FGFR2 and 3 proteins have a role in the prognosis of urothelial bladder carcinoma?
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
236P - The effects of chemotherapy on body composition in patients with advanced urothelial carcinoma
Presenter: KOSUKE KITAMURA
Session: Poster Display
Resources:
Abstract
237P - Real-world analysis of adjuvant nivolumab in resected urothelial cancer: A single institute study in Taiwanese patients
Presenter: Mu-Hsin Chang
Session: Poster Display
Resources:
Abstract